Audentes Therapeutics — Technical Presentation (May 2019)
29 slides from Audentes Therapeutics's technical presentation, May 1, 2019
Slide 1: ASPIRO Phase 1/2 Gene Therapy Trial in XLMTM: Update on Preliminary Safety and Efficacy Findings
ASPIRO Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety and Efficacy Findings Perry Shieh, MD PhD Associate Professor of Neurology, University of California Los Angeles Exhibit 99.2
Slide 2: Disclosures
Disclosures Principal Investigator in the INCEPTUS and ASPIRO XLMTM clinical trials Advisory boards Audentes, Sarepta, Roche, Avexis, Biogen Speakers’ bureau Biogen, Alexion, CSL Behring, Grifols
Slide 3: MTM1 gene produces myotubularin protein; X-Linked Myotubular Myopathy
MTM1 gene produces myotubularin protein1 Myotubularin dephosphorylates critical second messenger proteins 1 2 3 Myotubularin required for correct Muscle growth and differentiation2,3 Cellular organization and structure2–4 Cellular function2,4,5 SR SR, sarcoplasmic reticulum Raess MA, et al. Adv Biol
Slide 4: XLMTM – Natural History
Annoussamy M, et al. Neurology 2019;92:e1852–67 Beggs AH, et al. Muscle Nerve 2018;57:550–60 Vandersmissen I, et al. Neuromuscul Disord 2018;28:766–7 Amburgey K, et al. Neurology 2017;89:1355–64 XLMTM – Natural History Incidence ≈1 in 40–50K newborn males1–4 Estimated 50% mortality by 18 months2 10-
Slide 5: AT132: rAAV8-Des-hMTM1
ITR, inverted terminal repeat; Des, human desmin promoter polyA, polyadenylation signal; SA, splice acceptor; SD, splice donor 1. Mack DL, et al. Mol Ther 2017;25:839–54 AT132: rAAV8-Des-hMTM1 First systemic gene therapy utilizing the muscle-specific desmin promoter AAV8 effectively transduces skele
Slide 6: ASPIRO Phase 1/2 Clinical Study of AT132
CHOP INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders BL, baseline; mo, months; Wk, week ASPIRO, NCT03199469; INCEPTUS, NCT02704273 ASPIRO Phase 1/2 Clinical Study of AT132 An open-label, ascending-dose, safety and preliminary efficacy study AT132 administration Inc
Slide 7: ASPIRO Patient Enrollment and Follow-up
ASPIRO Patient Enrollment and Follow-up Eleven patients enrolled in the INCEPTUS observational run-in study have transitioned into ASPIRO Interim data as of April 8, 2019 Duration in the study (years) Age at dosinga (years) Cohort 1 Cohort 2 Patient ID 0.8 4.1 2.5 4 0.8 0.7 0.7 1.3 6.8 2.3 2.4 Follo
Slide 8: Safety and Tolerability
Safety and Tolerability
Slide 9: AT132 Well Tolerated with Manageable Safety Profile
Since the initiation of the study (Sep 2017): there are 47 AEs (including SAEs) considered related/possibly related. There are 35 non-serious AEs related/possibly related Interim data as of April 8, 2019 Cohort 1: 1x1014vg/kg; Cohort 2: 3x1014vg/kg; AE, adverse event; CK, creatine kinase AT132 Well
Slide 10: Muscle Biopsy
Muscle Biopsy
Slide 11: Robust Transduction, Transcription and Protein Expression
Cohort 1: 1x1014vg/kg; Cohort 2: 3x1014vg/kg Interim data as April 8, 2019 Robust Transduction, Transcription and Protein Expression AT132 produced dose-dependent increases in the gastrocnemius muscle at Week 24 Patient 1 Patient 2 Patient 3 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient
Slide 12: Molecular Findings Consistent Across Muscle Groups
Patient 1 Patient 2 Patient 3 Patient 5 Patient 6 Patient 7 MTM1 mRNA ratio (Transgene:Reference gene) Interim data as April 8, 2019 Molecular Findings Consistent Across Muscle Groups Cohort 1 showed robust increases in transduction, transcription, and protein expression in the vastus lateralis musc
Slide 13: Improvement in Histopathological Hallmarks of XLMTM Cohort 1
H&E NADH Healthy 5-year-old Baseline Week 24 Week 48 Improvement in Histopathological Hallmarks of XLMTM Cohort 1 Representative Histology Baseline – Classic XLMTM pathology including fiber smallness, internally placed nuclei, and central aggregates of organelles on NADH stain Week 24 – Organelle mi
Slide 14: Histopathological Findings in Cohort 2 Suggest More Rapid Rate of Pathological Recovery
Healthy 2-year-old Baseline Week 24 Histopathological Findings in Cohort 2 Suggest More Rapid Rate of Pathological Recovery Cohort 1: 1x1014vg/kg; Cohort 2: 3x1014vg/kg H&E, hematoxylin and eosin; NADH, nicotinamide adenine dinucleotide Cohort 2 Representative Histology Cohort 2 biopsy at Week 24 sh
Slide 15: Neuromuscular Function: CHOP INTEND and Developmental Milestones
Neuromuscular Function CHOP INTEND and Developmental Milestones
Slide 16: Significant Improvements in Neuromuscular Function
64 Control patients Patient ID Baseline score Latest score Change from baseline (%) Cohort 1 1 29 56 (Wk48) +93 2 45 64 (Wk48) +42 3 34 39 (Wk48) +15 4 49 47 (Wk48) -4 5 36 63 (Wk48) +75 6 39 53 (Wk48) +36 7 43 64 (Wk48) +49 Cohort 2 8 36 61 (Wk24) +69 9 39 55 (Wk24) +41 10 29 46 (Wk24) +59 11 42 37
Slide 17: Mean Increase in CHOP INTEND Score
CHOP INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders BL, baseline; LS, Least Squares Bars indicate standard error Interim data as of April 8, 2019 LS Mean Increase in CHOP INTEND Score Treated patients showed sustained clinical improvements in motor function Treate
Slide 18: Motor Milestones: Head Control
Motor Milestones: Head Control Treated patients show progressive attainment of milestones regardless of age Months after birth Age 1 Age 2 Age 3 Age 4 Age 5 Age 6 Age 7 1 2 3 4 5 6 7 8 9 10 11 12 Head control 1 11 2 9 5 10 4 6 7 8 Interim data as of April 8, 2019 Patient 3 not evaluable because of h
Slide 19: Motor Milestones: Rolling From Back to Stomach
Motor Milestones: Rolling From Back to Stomach Treated patients show progressive attainment of milestones regardless of age Months after birth Age 1 Age 2 Age 3 Age 4 Age 5 Age 6 Age 7 1 2 3 4 5 6 7 8 9 10 11 12 Rolling from back to stomach 1 11 2 9 5 10 4 6 7 8 Interim data as of April 8, 2019 Pati
Slide 20: Motor Milestones: Sitting 30 sec Without Support
Motor Milestones: Sitting 30 sec Without Support Treated patients show progressive attainment of milestones regardless of age Months after birth Age 1 Age 2 Age 3 Age 4 Age 5 Age 6 Age 7 1 2 3 4 5 6 7 8 9 10 11 12 Sitting 30 sec without support 1 11 2 9 5 10 4 6 7 8 Interim data as of April 8, 2019
Slide 21: Motor Milestones: Makes Stepping Movements
Motor Milestones: Makes Stepping Movements Treated patients show progressive attainment of milestones regardless of age Months after birth Age 1 Age 2 Age 3 Age 4 Age 5 Age 6 Age 7 1 2 3 4 5 6 7 8 9 10 11 12 Makes stepping movements 1 11 2 9 5 10 4 6 7 8 Interim data as of April 8, 2019 Patient 3 no
Slide 22: Respiratory Function: MIP and Ventilator Dependence
Respiratory Function Maximal Inspiratory Pressure (MIP) and Ventilator Dependence
Slide 23: Significant Improvements in Respiratory Function
MIP 80 cmH2O: Estimated lower limit of normal in healthy children <5 years of age MIP (cmH2O) Weeks after ASPIRO baseline BL Uncuffed tracheostomy, gas leak: Patients 7 and 8 Significant Improvements in Respiratory Function Interim data as of April 8, 2019 MIP, maximum inspiratory pressure BL, basel
Slide 24: Sustained Clinically Meaningful Improvement in Respiratory Strength
MIP, maximal inspiratory pressure; ctrl, control; BL, baseline; Wk, week LS, Least Squares means estimated with Repeated Measures ANOVA Model Bars indicate standard error Interim data as April 8, 2019 Sustained Clinically Meaningful Improvement in Respiratory Strength in Treated Patients Weeks after
Slide 25: Significant and Rapid Reductions in Ventilator Use in All Treated Patients
Significant and Rapid Reductions in Ventilator Use in All Treated Patients Interim data as of April 8, 2019 Cohort 1: 1x1014vg/kg; Cohort 2: 3x1014vg/kg BiPAP, bilevel positive airway pressure; BL, baseline; Inv, invasive; Wk, week Ventilator independence achieved by 4 patients to date Interim data
Slide 26: Reductions in Ventilator Dependence Not Previously Observed in NMD
NMD, neuromuscular disease; BL, baseline; LS, Least Squares means estimated with Repeated Measures ANOVA Model Bars indicate standard error Interim data as April 8, 2019 Treated Patients Have Achieved Reductions in Ventilator Dependence Not Previously Observed in Chronically Ventilated Patients with
Slide 27: Patient Video
Patient Video Please: No photographic or video recordings of patient videos
Slide 28: Key Findings to Date of ASPIRO
Interim data as of April 8, 2019 ASPIRO Key Findings to Date AT132 has been generally well tolerated and has shown manageable safety profile across both dose cohorts Muscle biopsies show robust dose-dependent transduction, transcription, protein expression and histological improvements through Week
Slide 29: Acknowledgements
Acknowledgements XLMTM Preclinical Studies and ASPIRO Clinical Trial Anna Buj Bello Genethon Martin K. (Casey) Childers David Mack University of Washington, USA Alan H. Beggs Children’s Hospital Boston, USA Michael W. Lawlor Children’s Hospital and Medical College of Wisconsin, USA My team at the UC
Audentes Therapeutics — Technical Presentation (May 2019) on 6ix